High-fat diet-dependent activation of the DNA damage response as an underlying mechanism of prostate cancer aggressiveness

Anna de Polo1, Nadia Boufaied1, Myriam Harbec1, Isabelle Clément2, Michelle Shen1, Aurélie Le Page1, Giorgia Zadra3,4, Massimo Lodas, Myles Brown6,7, Dominique Trudel2, Francis Rodier2, David P. Labbé1

1Division of Urology, Department of Surgery, McGill University and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
2CRCHUM et Institut du cancer de Montréal, Université de Montréal, Montréal, Québec, Canada
3Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, US
4Department of Pathology, Brigham and Women’s Hospital, Boston, MA, US
5Department of Pathology and Laboratory Medicine, Weil Cornell Medicine, New York Presbyterian-Weill Cornell Campus, New York, NY, US
6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, US
7Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, US

Background: The large worldwide disparity in prostate cancer (PCa) incidence points to a key role of environmental factors, such as diet, in PCa etiology. Epidemiological studies have reported that increased consumption of saturated fat can severely affect PCa progression and mortality, but the molecular underpinnings of this association are poorly understood.

Methods: We used a genetically engineered mouse model of PCa driven by c-MYC overexpression (Hi-MYC) and the associated MyC-CaP murine PCa cell line to investigate the effect of high-fat diet (HFD) in vivo and in vitro. Transcriptomics analyses (RNA-seq), immunofluorescence staining and western blot analyses were performed on tumor tissues. Plasma collected from mice fed defined diets was used for in vitro treatments. We also leveraged dietary intake and transcriptomics data from the Health Professional Follow-up Study (HPFS) and Physicians’ Health Study (PHS).

Results: Dietary manipulation of MYC-driven murine PCa models showed that tumors grown in mice maintained on a HFD rich in animal-derived saturated fats were more aggressive, displayed an enhanced DNA repair transcriptional signature and elevated levels of γH2A.X (a marker of DNA damage) compared to tumors from control diet (CTD)-fed mice. We hypothesized that metabolic alterations associated with HFD affect the execution of the DNA damage response (DDR) in PCa cells, inducing increased genomic instability that ultimately fuels PCa aggressiveness. Accordingly, an activation of the ATM/Chk2/p53 pathway was observed in tumors from the HFD-fed mice. Importantly, in vitro treatment of MyC-CaP cells with plasma collected from mice submitted to a short-term HFD intervention recapitulated the activation of the ATM/Chk2/p53 pathway and induced a down-regulation of the ATR/Chk1 pathway, two different arms of DDR signaling. Finally, we show that saturated fat intake, but not monounsaturated or polyunsaturated fat intake is also associated with an enhanced DNA repair transcriptional signature in the tumor of PCa patients.

Conclusions: Our findings suggest that a HFD rich in saturated fats fuels genomic instability and tumour aggressiveness at least partly by deregulating the DDR, setting the stage for therapeutic approaches involving changes to the diet.

Conflict of Interest: M.B. receives sponsored research support from Novartis and serves on the scientific advisory boards of H3 Biomedicine and Kronos Bio.

Funding Acknowledgments: G.Z. is a recipient of the Idea Development Award from the U.S. Department of Defense (PC150263) and the Barr Award from the Dana-Farber Cancer Institute. D.T. is a Clinical Research Scholar – Junior 2 from the Fonds de Recherche du Québec – Santé (FRQS). D.P.L is a Lewis Katz – Young Investigator of the Prostate Cancer Foundation (PCF), and is the recipient of a Scholarship for the Next Generation of Scientists from the Cancer Research Society (CRS), and is also a Research Scholar – Junior 1 from the FRQS. The work reported here was supported by grants from the Québec Astellas-Institut du cancer de Montréal to D.T. F.R. & D.P.L. and from the CRS and PCF to D.P.L.